Zealand Pharma As Stock Net Income
| ZLDPF Stock | USD 104.20 1.45 1.41% |
Zealand Pharma AS fundamentals help investors to digest information that contributes to Zealand Pharma's financial success or failures. It also enables traders to predict the movement of Zealand Pink Sheet. The fundamental analysis module provides a way to measure Zealand Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zealand Pharma pink sheet.
Zealand |
Zealand Pharma AS Company Net Income Analysis
Zealand Pharma's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Zealand Pharma Net Income | (1.02 B) |
Most of Zealand Pharma's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Zealand Pharma AS reported net income of (1.02 Billion). This is 398.33% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Zealand Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.Zealand Pharma is currently under evaluation in net income category among its peers.
Zealand Fundamentals
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X | |||
| Revenue | 292.57 M | |||
| Gross Profit | 173.75 M | |||
| EBITDA | (982.6 M) | |||
| Net Income | (1.02 B) | |||
| Cash And Equivalents | 864.44 M | |||
| Cash Per Share | 18.68 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.96 % | |||
| Current Ratio | 3.83 X | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (3.26) X | |||
| Target Price | 22.4 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 | |||
| Market Capitalization | 1.57 B | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | (1.24 B) | |||
| Working Capital | 356 M | |||
| Current Asset | 408 M | |||
| Current Liabilities | 52 M | |||
| Z Score | 1.2 | |||
| Net Asset | 2.07 B |
About Zealand Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.